Consolidation

PRA to buy CRI Lifetree

breaking news

PRA to buy CRI Lifetree

By Gareth Macdonald

US CRO PRA International has announced plans to buy privately-owned early phase trial specialist CRI Lifetree.

DrugDev acquires site payment specialist CFS Clinical

DrugDev acquires site payment specialist CFS Clinical

By Zachary Brennan

Sponsor network developer DrugDev on Monday announced it would acquire CFS Clinical, which specializes in managing the financing of clinical trials.  Financial terms were not disclosed.

Cambridge Major Labs and AAIPharma Merge

Cambridge Major Labs and AAIPharma Merge

By Dan Stanton

AAIPharma says the merger with Cambridge Major Laboratories (CML) will bring clients the benefits of integrated Chemistry and Manufacturing Controls (CMC) services from two high-growth CMOs.

PRA completes merger of RPS

PRA completes merger of RPS

The merger of PRA and RPS has been completed, creating the fourth largest contract research organisation (CRO).

CRA Buys Psychiatric Trial Firm

CRA Buys Psychiatric Trial Firm CCD

By Dan Stanton

Clinical Research Advantage (CRA) has acquired the late phase business of Comprehensive Clinical Development (CCD) adding psychiatric clinical trials to its services.

M&A, partnerships and new services in pharma outsourcing

New pharma services from M&A and partnerships: round-up

By Natalie Morrison

Outsourcing-Pharma.com presents the low down on new services forged by partnerships and M&A (mergers and acquisitions), including a molecular biology offering for Quotient, Onyx’s added purification and separation capabilities, and Accenture’s new...

BioFocus: new HTS compound portfolio management system

BioFocus gives itself room to update compound library

By Natalie Morrison

BioFocus has taken on Titian’s sample management software in a bid to pump more resources into “refreshing” its 900,000 strong high-throughput screening (HTS) compound portfolio.

DPT Renaissance acquisition Confab CDMO

No cuts at DPT Labs says new owner Renaissance Pharma

By Gareth Macdonald

No job losses, facility divestitures or strategic changes are planned at DPT Laboratories according to new owner Renaissance Pharma, which bought the CDMO in an out-of-the-blue deal last week.